Non-alcoholic fatty liver disease and dyslipidemia: An update

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1109-1123

  Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b   Mantzoros, Christos S ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antidiabetic drugs; Dyslipidemia; Ezetimibe; Non alcoholic fatty liver disease; Statins

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; APOLIPOPROTEIN; BIOLOGICAL MARKER; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; METFORMIN; MICRORNA; NICOTINIC ACID; OBETICHOLIC ACID; PENTOXIFYLLINE; PIOGLITAZONE;

ABDOMINAL AORTA ANEURYSM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SLEEP DISORDERED BREATHING; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; WEIGHT REDUCTION; COMPLICATION; DISEASE COURSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY;

DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS;

EID: 84969961723     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.05.003     Document Type: Review

References (301)

1. [1] Demir, M., Lang, S., Steffen, H.M., Nonalcoholic fatty liver disease – current status and future directions. J Dig Dis 16:10 (2015), 541–557.
2. [2] Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., Persico, M., Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 9:3 (2014), 126–133.
3. [3] Bhala, N., Jouness, R.I., Bugianesi, E., Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 19:29 (2013), 5169–5176.
4. [4] Mishra, A., Younossi, Z.M., Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2:2 (2012), 135–144.
5. [5] Carr, R.M., Ahima, R.S., Pathophysiology of lipid droplet proteins in liver diseases. Exp Cell Res 340:2 (2016), 187–192.
6. [6] Mashek, D.G., Khan, S.A., Sathyanarayan, A., Ploeger, J.M., Franklin, M.P., Hepatic lipid droplet biology: Getting to the root of fatty liver. Hepatology 62:3 (2015), 964–967.
7. [7] Sahini, N., Borlak, J., Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res 54 (2014), 86–112.
8. [8] Almeda-Valdes, P., Altamirano-Barrera, A., Méndez-Sánchez, N., Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses. Ann Hepatol 14:4 (2015), 567–569.
9. [9] Ress, C., Kaser, S., Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol 22:4 (2016), 1664–1673.
10. [10] Polyzos, S.A., Aronis, K.N., Kountouras, J., Raptis, D.D., Vasiloglou, M.F., Mantzoros, C.S., Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Diabetologia 59:1 (2016), 30–43.
11. [11] Polyzos, S.A., Kountouras, J., CS, M., Adipokines in nonalcoholic fatty liver disease. Metabolism 65 (2015), 1062–1079.
12. [12] Polyzos, S.A., Kountouras, J., Mantzoros, C.S., Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64:1 (2015), 60–78.
13. [13] Bekaert, M., Verhelst, X., Geerts, A., Lapauw, B., Calders, P., Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes Rev 17:1 (2016), 68–80.
14. [14] Zeng, L., Tang, W.J., Yin, J.J., Zhou, B.J., Signal transductions and nonalcoholic fatty liver: A mini-review. Int J Clin Exp Med. 7:7 (2014), 1624–1631.
15. [15] Abenavoli, L., Peta, V., Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 9:3 (2014), 134–140.
16. [16] Lim, J.W., Dillon, J., Miller, M., Proteomic and genomic studies of non-alcoholic fatty liver disease – clues in the pathogenesis. World J Gastroenterol 20:26 (2014), 8325–8340.
17. [17] Stojsavljević, S., Gomerčić Palčić, M., Virović Jukić, L., Smirčić Duvnjak, L., Duvnjak, M., Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 20:48 (2014), 18070–18091.
18. [18] Lau, E., Carvalho, D., Freitas, P., Gut microbiota: Association with NAFLD and metabolic disturbances. Biomed Res Int., 2015, 2015, 979515.
19. [19] Kirpich, I.A., Marsano, L.S., McClain, C.J., Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 48:13–14 (2015), 923–930.
20. [20] Milić, S., Lulić, D., Štimac, D., Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 20:28 (2014), 9330–9337.
21. [21] Fabbrini, E., Magkos, F., Hepatic steatosis as a marker of metabolic dysfunction. Nutrients. 7:6 (2015), 4995–5019.
22. [22] Byrne, C.D., Targher, G., NAFLD: A multisystem disease. J Hepatol 62:1Suppl (2015), S47–S64.
23. [23] Musso, G., Cassader, M., Cohney, S., Pinach, S., Saba, F., Gambino, R., Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med 21:10 (2015), 645–662.
24. [24] Musso, G., Gambino, R., Tabibian, J.H., Ekstedt, M., Kechagias, S., Hamaguchi, M., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med, 11(7), 2014, e1001680.
25. [25] Azzam, H., Malnick, S., Non-alcoholic fatty liver disease – the heart of the matter. World J Hepatol. 7:10 (2015), 1369–1376.
26. [26] Athyros, V.G., Katsiki, N., Doumas, M., Karagiannis, A., Mikhailidis, D.P., Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: A narrative review. Curr Med Res Opin 29:10 (2013), 1263–1274.
27. [27] Grundy, S.M., Metabolic syndrome update. Trends Cardiovasc Med, 2015 [pii: S1050-1738(15)00249-2].
28. [28] Zhang, Q.Q., Lu, L.G., Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 3:1 (2015), 78–84.
29. [29] Chatrath, H., Vuppalanchi, R., Chalasani, N., Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 32:1 (2012), 22–29.
30. [30] Tenenbaum, A., Klempfner, R., Fisman, E.Z., Hypertriglyceridemia: A too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol, 13, 2014, 159.
31. [31] Graham, I., Cooney, M.T., Bradley, D., Dudina, A., Reiner, Z., Dyslipidemias in the prevention of cardiovascular disease: Risks and causality. Curr Cardiol Rep 14:6 (2012), 709–720.
32. [32] Lim, S., Park, Y.M., Sakuma, I., Koh, K.K., How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 166:1 (2013), 8–14.
33. [33] Mureddu, G.F., Brandimarte, F., De Luca, L., High-density lipoprotein levels and risk of cardiovascular events: A review. J Cardiovasc Med (Hagerstown) 13:9 (2012), 575–586.
34. [34] Bril, F., Sninsky, J.J., Baca, A.M., Superko, H.R., Portillo Sanchez, P., Biernacki, D., et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab 101:2 (2016), 644–652.
35. [35] Kikkawa, K., Nakajima, K., Shimomura, Y., Tokita, Y., Machida, T., Sumino, H., et al. Small dense LDL cholesterol measured by homogeneous assay in Japanese health controls, metabolic syndrome and diabetes patients with or without a fatty liver. Clin Chim Acta 438 (2015), 70–79.
36. [36] Sugino, I., Kuboki, K., Matsumoto, T., Murakami, E., Nishimura, C., Yoshino, G., Influence of fatty liver on plasma small, dense LDL- cholesterol in subjects with and without metabolic syndrome. J Atheroscler Thromb 18:1 (2011), 1–7.
37. [37] Nikolic, D., Katsiki, N., Montalto, G., Isenovic, E.R., Mikhailidis, D.P., Rizzo, M., Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 5:3 (2013), 928–948.
38. [38] Imajo, K., Hyogo, H., Yoneda, M., Honda, Y., Kessoku, T., Tomeno, W., et al. LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: A multicenter cross-sectional study. PLoS One, 9(12), 2014, e115403.
39. [39] Sonmez, A., Nikolic, D., Dogru, T., Ercin, C.N., Genc, H., Cesur, M., et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol 9:4 (2015), 576–582.
40. [40] Tariq, S.M., Sidhu, M.S., Toth, P.P., Boden, W.E., HDL hypothesis: Where do we stand now?. Curr Atheroscler Rep, 16(4), 2014, 398.
41. [41] Kakafika, A., Athyros, V.G., Tziomalos, K., Karagiannis, A., Mikhailidis, D.P., High density lipoprotein cholesterol and statin trials. Curr Med Chem 15:22 (2008), 2265–2270.
42. [42] Kosmas, C.E., Christodoulidis, G., Cheng, J.W., Vittorio, T.J., Lerakis, S., High-density lipoprotein functionality in coronary artery disease. Am J Med Sci 347:6 (2014), 504–508.
43. [43] Otocka-Kmiecik, A., Mikhailidis, D.P., Nicholls, S.J., Davidson, M., Rysz, J., Banach, M., Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res 51:4 (2012), 314–324.
44. [44] Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Should raising high-density lipoprotein cholesterol be a matter of debate?. J Cardiovasc Med (Hagerstown) 13:4 (2012), 254–259.
45. [45] Florentin, M., Liberopoulos, E.N., Wierzbicki, A.S., Mikhailidis, D.P., Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23:4 (2008), 370–378.
46. [46] Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., High-density lipoprotein, vascular risk, cancer and infection: A case of quantity and quality?. Curr Med Chem 21:25 (2014), 2917–2926.
47. [47] Kantartzis, K., Rittig, K., Cegan, A., Machann, J., Schick, F., Balletshofer, B., et al. Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions. Diabetes Care 31:2 (2008), 366–368.
48. [48] Corey, K.E., Misdraji, J., Gelrud, L., Zheng, H., Chung, R.T., Krauss, R.M., Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis, 13, 2014, 100.
49. [49] Stefanutti, C., Labbadia, G., Athyros, V.G., Hypertriglyceridaemia, postprandial lipaemia and non-HDL cholesterol. Curr Pharm Des 20:40 (2014), 6238–6248.
50. [50] Kolovou, G., Ooi, T.C., Postprandial lipaemia and vascular disease. Curr Opin Cardiol 28:4 (2013), 446–451.
51. [51] Chan, D.C., Pang, J., Romic, G., Watts, G.F., Postprandial hypertriglyceridemia and cardiovascular disease: Current and future therapies. Curr Atheroscler Rep, 15(3), 2013, 309.
52. [52] Kolovou, G.D., Mikhailidis, D.P., Kovar, J., Lairon, D., Nordestgaard, B.G., Ooi, T.C., et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9:3 (2011), 258–270.
53. [53] Kolovou, G.D., Mikhailidis, D.P., Nordestgaard, B.G., Bilianou, H., Panotopoulos, G., Definition of postprandial lipaemia. Curr Vasc Pharmacol 9:3 (2011), 292–301.
54. [54] Musso, G., Gambino, R., De Michieli, F., Cassader, M., Rizzetto, M., Durazzo, M., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:4 (2003), 909–916.
55. [55] Musso, G., Gambino, R., Durazzo, M., Biroli, G., Carello, M., Fagà, E., et al. Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 42:5 (2005), 1175–1183.
56. [56] Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Characteristics other than the diagnostic criteria associated with metabolic syndrome: An overview. Curr Vasc Pharmacol 12:4 (2014), 627–641.
57. [57] Pirillo, A., Norata, G.D., Catapano, A.L., Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin 30:8 (2014), 1489–1503.
58. [58] Garcia-Rios, A., Delgado-Lista, J., Perez-Martinez, P., Delgado-Casado, N., Perez-Jimenez, F., Lopez-Miranda, J., Relevance of postprandial lipemia in metabolic syndrome. Curr Vasc Pharmacol 11:6 (2013), 920–927.
59. [59] Kassner, U., Schlabs, T., Rosada, A., Steinhagen-Thiessen, E., Lipoprotein(a) – an independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl 18 (2015), 263–267.
60. [60] Hoover-Plow, J., Huang, M., Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism 62:4 (2013), 479–491.
61. [61] Lee, S., Jin Kim, Y., Yong Jeon, T., Hoi Kim, H., Woo Oh, S., Park, Y., et al. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: A cross-sectional case–control study. Scand J Gastroenterol 41:5 (2006), 566–572.
62. [62] Yang, M.H., Son, H.J., Sung, J.D., Choi, Y.H., Koh, K.C., Yoo, B.C., et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepatogastroenterology 52:66 (2005), 1832–1835.
63. [63] Wu, C.L., Zhao, S.P., Yu, B.L., Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non-alcoholic fatty liver disease. Biol Rev Camb Philos Soc 90:2 (2015), 367–376.
64. [64] Feng, Q., Baker, S.S., Liu, W., Arbizu, R.A., Aljomah, G., Khatib, M., et al. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers. Pathology 47:4 (2015), 341–348.
65. [65] Forte, T.M., Ryan, R.O., Apolipoprotein A5: Extracellular and intracellular roles in triglyceride metabolism. Curr Drug Targets 16:12 (2015), 1274–1280.
66. [66] Ress, C., Moschen, A.R., Sausgruber, N., Tschoner, A., Graziadei, I., Weiss, H., et al. The role of apolipoprotein A5 in non-alcoholic fatty liver disease. Gut 60:7 (2011), 985–991.
67. [67] Tilg, H., Moschen, A., Update on nonalcoholic fatty liver disease: Genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care 13:4 (2010), 391–396.
68. [68] Sazci, A., Akpinar, G., Aygun, C., Ergul, E., Senturk, O., Hulagu, S., Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci 53:12 (2008), 3218–3224.
69. [69] Demirag, M.D., Onen, H.I., Karaoguz, M.Y., Dogan, I., Karakan, T., Ekmekci, A., et al. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig Dis Sci 52:12 (2007), 3399–3403.
70. [70] Kohan, A.B., Apolipoprotein C-III: A potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 22:2 (2015), 119–125.
71. [71] Lopez, M.F., Krastins, B., Ning, M., The role of apolipoprotein E in neurodegeneration and cardiovascular disease. Expert Rev Proteomics 11:3 (2014), 371–381.
72. [72] Khan, T.A., Shah, T., Prieto, D., Zhang, W., Price, J., Fowkes, G.R., et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 42:2 (2013), 475–492.
73. [73] Forte, T.M., Sharma, V., Ryan, R.O., Apolipoprotein A-V gene therapy for disease prevention/treatment: A critical analysis. J Biomed Res, 30, 2015.
74. [74] Zheng, C., Updates on apolipoprotein CIII: Fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 25:1 (2014), 35–39.
75. [75] Otarod, J.K., Goldberg, I.J., Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 6:5 (2004), 335–342.
76. [76] Talmud, P.J., Stephens, J.W., Lipoprotein lipase gene variants and the effect of environmental factors on cardiovascular disease risk. Diabetes Obes Metab 6:1 (2004), 1–7.
77. [77] Pardina, E., Baena-Fustegueras, J.A., Llamas, R., Catalán, R., Galard, R., Lecube, A., et al. Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis. Obes Surg 19:5 (2009), 608–616.
78. [78] Miksztowicz, V., Lucero, D., Zago, V., Cacciagiú, L., Lopez, G., Gonzalez Ballerga, E., et al. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev 28:6 (2012), 535–541.
79. [79] Pisto, P., Santaniemi, M., Bloigu, R., Ukkola, O., Kesäniemi, Y.A., Fatty liver predicts the risk for cardiovascular events in middle-aged population: A population-based cohort study. BMJ Open., 4(3), 2014, e004973.
80. [80] Gaudio, E., Nobili, V., Franchitto, A., Onori, P., Carpino, G., Nonalcoholic fatty liver disease and atherosclerosis. Intern Emerg Med 7:Suppl. 3 (2012), S297–S305.
81. [81] Hamaguchi, M., Kojima, T., Takeda, N., Nagata, C., Takeda, J., Sarui, H., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13:10 (2007), 1579–1584.
82. [82] Targher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:12 (2005), 3541–3546.
83. [83] Fargion, S., Porzio, M., Fracanzani, A.L., Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol 20:37 (2014), 13306–13324.
84. [84] Vilar, C.P., Cotrim, H.P., Florentino, G.S., Barreto, C.P., Florentino, A.V., Bragagnoli, G., et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Rev Assoc Med Bras 59:3 (2013), 290–297.
85. [85] Nseir, W., Shalata, A., Marmor, A., Assy, N., Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci 56:12 (2011), 3439–3449.
86. [86] Lioudaki, E., Ganotakis, E.S., Mikhailidis, D.P., Liver enzymes: Potential cardiovascular risk markers?. Curr Pharm Des 17:33 (2011), 3632–3643.
87. [87] Targher, G., Byrne, C.D., Circulating markers of liver function and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 35:11 (2015), 2290–2296.
88. [88] Sookoian, S., Pirola, C.J., Liver enzymes, metabolomics and genome-wide association studies: From systems biology to the personalized medicine. World J Gastroenterol 21:3 (2015), 711–725.
89. [89] Kunutsor, S.K., Apekey, T.A., Khan, H., Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. Atherosclerosis 236:1 (2014), 7–17.
90. [90] Bonci, E., Chiesa, C., Versacci, P., Anania, C., Silvestri, L., Pacifico, L., Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: A systematic review and meta-analysis. Biomed Res Int, 2015, 2015, 213737.
91. [91] Sinn, D.H., Cho, S.J., Gwak, G.Y., Cho, J., Gu, S., Seong, D., et al. Nonalcoholic fatty liver disease for identification of preclinical carotid atherosclerosis. Medicine (Baltimore), 95(3), 2016, e2578.
92. [92] Sookoian, S., Pirola, C.J., Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 49:4 (2008), 600–607.
93. [93] Cai, J., Zhang, S., Huang, W., Association between nonalcoholic fatty liver disease and carotid atherosclerosis: A meta-analysis. Int J Clin Exp Med 8:5 (2015), 7673–7678.
94. [94] Madan, S.A., John, F., Pyrsopoulos, N., Pitchumoni, C.S., Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: A meta-analysis. Eur J Gastroenterol Hepatol 27:11 (2015), 1237–1248.
95. [95] Bhatia, L., Scorletti, E., Curzen, N., Clough, G.F., Calder, P.C., Byrne, C.D., Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis 246 (2016), 13–20.
96. [96] Koumaras, C., Katsiki, N., Athyros, V.G., Karagiannis, A., Metabolic syndrome and arterial stiffness: The past, the present and the future. J Cardiovasc Med (Hagerstown) 14:10 (2013), 687–689.
97. [97] Katsiki, N., Koumaras, C., Athyros, V.G., Karagiannis, A., Thinking beyond traditional cardiovascular risk factors: The role of arterial stiffness in targeting residual risk. Angiology 63:1 (2012), 9–11.
98. [98] Katsiki, N., Kolovou, G., Smoking and arterial stiffness. Angiology 66:10 (2015), 969–970.
99. [99] Doonan, R.J., Hausvater, A., Scallan, C., Mikhailidis, D.P., Pilote, L., Daskalopoulou, S.S., The effect of smoking on arterial stiffness. Hypertens Res 33:5 (2010), 398–410.
100. [100] Seifalian, A.M., Filippatos, T.D., Joshi, J., Mikhailidis, D.P., Obesity and arterial compliance alterations. Curr Vasc Pharmacol 8:2 (2010), 155–168.
101. [101] Wu, C.F., Liu, P.Y., Wu, T.J., Hung, Y., Yang, S.P., Lin, G.M., Therapeutic modification of arterial stiffness: An update and comprehensive review. World J Cardiol 7:11 (2015), 742–753.
102. [102] Koumaras, C., Tzimou, M., Stavrinou, E., Griva, T., Gossios, T.D., Katsiki, N., et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 12:3 (2012), 143–156.
103. [103] Vlachopoulos, C., Aznaouridis, K., Stefanadis, C., Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol 55:13 (2010), 1318–1327.
104. [104] Ikonomidis, I., Makavos, G., Lekakis, J., Arterial stiffness and coronary artery disease. Curr Opin Cardiol 30:4 (2015), 422–431.
105. [105] van den Oord, S.C., Sijbrands, E.J., ten Kate, G.L., van Klaveren, D., van Domburg, R.T., van der Steen, A.F., et al. Carotid intima-media thickness for cardiovascular risk assessment: Systematic review and meta-analysis. Atherosclerosis 228:1 (2013), 1–11.
106. [106] Charakida, M., Masi, S., Lüscher, T.F., Kastelein, J.J., Deanfield, J.E., Assessment of atherosclerosis: The role of flow-mediated dilatation. Eur Heart J 31:23 (2010), 2854–2861.
107. [107] Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Pichiri, I., et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One, 10(8), 2015, e0135329.
108. [108] Ballestri, S., Lonardo, A., Bonapace, S., Byrne, C.D., Loria, P., Targher, G., Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:7 (2014), 1724–1745.
109. [109] Ahmed, M.H., Barakat, S., Almobarak, A.O., Nonalcoholic fatty liver disease and cardiovascular disease: Has the time come for cardiologists to be hepatologists?. J Obes, 2012, 2012, 483135.
110. [110] Mellinger, J.L., Pencina, K.M., Massaro, J.M., Hoffmann, U., Seshadri, S., Fox, C.S., et al. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study. J Hepatol 63:2 (2015), 470–476.
111. [111] Oni, E.T., Agatston, A.S., Blaha, M.J., Fialkow, J., Cury, R., Sposito, A., et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230:2 (2013), 258–267.
112. [112] Valbusa, F., Bonapace, S., Grillo, C., Scala, L., Chiampan, A., Rossi, A., et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore), 95(7), 2016, e2760.
113. [113] Mantovani, A., Ballestri, S., Lonardo, A., Targher, G., Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci, 2016 Jan 25 [Epub ahead of print].
114. [114] Mantovani, A., Pernigo, M., Bergamini, C., Bonapace, S., Lipari, P., Valbusa, F., et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64:8 (2015), 879–887.
115. [115] Markus, M.R., Baumeister, S.E., Stritzke, J., Dörr, M., Wallaschofski, H., Völzke, H., et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: The Study Of Health In Pomerania (SHIP). Arterioscler Thromb Vasc Biol 33:7 (2013), 1690–1695.
116. [116] Käräjämäki, A.J., Pätsi, O.P., Savolainen, M., Kesäniemi, Y.A., Huikuri, H., Ukkola, O., Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One, 10(11), 2015, e0142937.
117. [117] Targher, G., Valbusa, F., Bonapace, S., Bertolini, L., Zenari, L., Rodella, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One, 8(2), 2013, e57183.
118. [118] Talman, A.H., Psaltis, P.J., Cameron, J.D., Meredith, I.T., Seneviratne, S.K., Wong, D.T., Epicardial adipose tissue: Far more than a fat depot. Cardiovasc Diagn Ther 4:6 (2014), 416–429.
119. [119] Toth, P.P., Epicardial steatosis, insulin resistance, and coronary artery disease. Heart Fail Clin 8:4 (2012), 671–678.
120. [120] Katsiki, N., Mikhailidis, D.P., Wierzbicki, A.S., Epicardial fat and vascular risk: A narrative review. Curr Opin Cardiol 28:4 (2013), 458–463.
121. [121] Iacobellis, G., Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol 11:6 (2015), 363–371.
122. [122] Iacobellis, G., Barbarini, G., Letizia, C., Barbaro, G., Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 22:2 (2014), 332–336.
123. [123] Petta, S., Argano, C., Colomba, D., Cammà, C., Di Marco, V., Cabibi, D., et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. J Hepatol 62:4 (2015), 928–933.
124. [124] Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285, 2001, 2486–2497.
125. [125] Targher, G., Bertolini, L., Padovani, R., Poli, F., Scala, L., Tessari, R., et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23:4 (2006), 403–409.
126. [126] Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:5 (2007), 1212–1218.
127. [127] Genest, J., McPherson, R., Frohlich, J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 25 (2009), 567–579.
128. [128] Reiner, Z., Catapano, A.L., De Backer, G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (2011), 1769–1818.
129. [129] Orlić, L., Mikolasevic, I., Bagic, Z., Racki, S., Stimac, D., Milic, S., Chronic kidney disease and nonalcoholic fatty liver disease – is there a link?. Gastroenterol Res Pract, 2014, 2014, 847539.
130. [130] Athyros, V.G., Tziomalos, K., Katsiki, N., Doumas, M., Karagiannis, A., Mikhailidis, D.P., Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 21:22 (2015), 6820–6834.
131. [131] Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Metabolic syndrome and non-cardiac vascular diseases: An update from human studies. Curr Pharm Des 20:31 (2014), 4944–4952.
132. [132] Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): A relationship with implications for vascular risk?. Curr Vasc Pharmacol 9:6 (2011), 698–705.
133. [133] Katsiki, N., Karagiannis, A., Athyros, V.G., Mikhailidis, D.P., Hyperuricaemia: More than just a cause of gout?. J Cardiovasc Med (Hagerstown) 14:6 (2013), 397–402.
134. [134] Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player. Eur J Intern Med, 15, 2015 Dec [Epub ahead of print].
135. [135] Li, L., Yang, C., Zhao, Y., Zeng, X., Liu, F., Fu, P., Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol, 15, 2014, 122.
136. [136] Bose, B., Badve, S.V., Hiremath, S.S., Boudville, N., Brown, F.G., Cass, A., et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant 29:2 (2014), 406–413.
137. [137] Viazzi, F., Leoncini, G., Ratto, E., Pontremoli, R., Hyperuricemia and renal risk. High Blood Press Cardiovasc Prev 21:3 (2014), 189–194.
138. [138] Shibagaki, Y., Ohno, I., Hosoya, T., Kimura, K., Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37:10 (2014), 919–925.
139. [139] Nakatsu, Y., Seno, Y., Kushiyama, A., Sakoda, H., Fujishiro, M., Katasako, A., et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol 309:1 (2015), G42–G51.
140. [140] Katsiki, N., Anagnostis, P., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., Psoriasis and vascular risk: An update. Curr Pharm Des 20:39 (2014), 6114–6125.
141. [141] Frostegård, J., Prediction and management of cardiovascular outcomes in systemic lupus erythematosus. Expert Rev Clin Immunol 11:2 (2015), 247–253.
142. [142] Prasad, M., Hermann, J., Gabriel, S.E., Weyand, C.M., Mulvagh, S., Mankad, R., et al. Cardiorheumatology: Cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12:3 (2015), 168–176.
143. [143] Giles, J.T., Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. Best Pract Res Clin Rheumatol 29:4–5 (2015), 597–613.
144. [144] Peters, M.J., Symmons, D.P., McCarey, D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69 (2010), 325–331.
145. [145] Grover, S., Rastogi, A., Singh, J., Rajbongshi, A., Bihari, C., Spectrum of histomorphologic findings in liver in patients with SLE: A review. Hepat Res Treat, 2014, 2014, 562979.
146. [146] Takahashi, A., Abe, K., Saito, R., Iwadate, H., Okai, K., Katsushima, F., et al. Liver dysfunction in patients with systemic lupus erythematosus. Intern Med 52:13 (2013), 1461–1465.
147. [147] Gisondi, P., Ferrazzi, A., Girolomoni, G., Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 18:4 (2010), 297–304.
148. [148] Takahashi, A., Abe, K., Yokokawa, J., Iwadate, H., Kobayashi, H., Watanabe, H., et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 40:11 (2010), 1092–1097.
149. [149] Doumas, M., Lazaridis, A., Katsiki, N., Athyros, V., PDE-5 inhibitors: Clinical points. Curr Drug Targets 16:5 (2015), 420–426.
150. [150] Katsiki, N., Athyros, V.G., Karagiannis, A., Wierzbicki, A.S., Mikhailidis, D.P., Should we expand the concept of coronary heart disease equivalents?. Curr Opin Cardiol 29:4 (2014), 389–395.
151. [151] Katsiki, N., Wierzbicki, A.S., Mikhailidis, D.P., Erectile dysfunction and coronary heart disease. Curr Opin Cardiol 30:4 (2015), 416–421.
152. [152] Vlachopoulos, C.V., Terentes-Printzios, D.G., Ioakeimidis, N.K., Aznaouridis, K.A., Stefanadis, C.I., Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: A systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 6:1 (2013), 99–109.
153. [153] Dong, J.Y., Zhang, Y.H., Qin, L.Q., Erectile dysfunction and risk of cardiovascular disease: Meta-analysis of prospective cohort studies. J Am Coll Cardiol 58:13 (2011), 1378–1385.
154. [154] Duman, D.G., Biçakci, E., Çelikel, Ç.A., Akbal, C., Nonalcoholic fatty liver disease is associated with erectile dysfunction: A prospective pilot study. J Sex Med 13:3 (2016), 383–388.
155. [155] Vignozzi, L., Filippi, S., Comeglio, P., Cellai, I., Sarchielli, E., Morelli, A., et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Mol Cell Endocrinol 384:1–2 (2014), 143–154.
156. [156] Pafili, K., Steiropoulos, P., Papanas, N., The relationship between obstructive sleep apnoea and coronary heart disease. Curr Opin Cardiol 30:4 (2015), 439–446.
157. [157] Gonzaga, C., Bertolami, A., Bertolami, M., Amodeo, C., Calhoun, D., Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens 29:12 (2015), 705–712.
158. [158] Mohsenin, V., Obstructive sleep apnea: A new preventive and therapeutic target for stroke: A new kid on the block. Am J Med 128:8 (2015), 811–816.
159. [159] Kostapanos, M.S., Mikhailidis, D.P., Elisaf, M.S., Steiropoulos, P., Papanas, N., Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci. 8:6 (2012), 1115–1116.
160. [160] Wang, J., Yu, W., Gao, M., Zhang, F., Li, Q., Gu, C., et al. Continuous positive airway pressure treatment reduces cardiovascular death and non-fatal cardiovascular events in patients with obstructive sleep apnea: A meta-analysis of 11 studies. Int J Cardiol 191 (2015), 128–131.
161. [161] Sookoian, S., Pirola, C.J., Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: A meta-analysis. Obes Surg 23:11 (2013), 1815–1825.
162. [162] Musso, G., Cassader, M., Olivetti, C., Rosina, F., Carbone, G., Gambino, R., Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 14:5 (2013), 417–431.
163. [163] Ahmed, M.H., Byrne, C.D., Obstructive sleep apnea syndrome and fatty liver: Association or causal link?. World J Gastroenterol 16:34 (2010), 4243–4252.
164. [164] Paschetta, E., Belci, P., Alisi, A., Liccardo, D., Cutrera, R., Musso, G., et al. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm, 2015, 2015, 815721.
165. [165] Eisele, H.J., Markart, P., Schulz, R., Obstructive sleep apnea, oxidative stress, and cardiovascular disease: Evidence from human studies. Oxid Med Cell Longev, 2015, 2015, 608438.
166. [166] Musso, G., Olivetti, C., Cassader, M., Gambino, R., Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: Emerging evidence and mechanisms. Semin Liver Dis 32:1 (2012), 49–64.
167. [167] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:6 (2012), 2005–2023.
168. [168] Mahady, S.E., George, J., Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 65 (2015), 1172–1182.
169. [169] Oliveira, C.P., de Lima, S.P., de Abreu-Silva, E.O., Marcadenti, A., Nutrition and physical activity in nonalcoholic fatty liver disease. J Diabetes Res, 2016, 2016, 4597246.
170. [170] Ryan, M.C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 59:1 (2013), 138–143.
171. [171] Dongiovanni, P., Lanti, C., Riso, P., Valenti, L., Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem 29 (2016 Mar), 1–11.
172. [172] Del Ben, M., Polimeni, L., Baratta, F., Pastori, D., Angelico, F., The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol, 6, 2016 Feb [Epub ahead of print].
173. [173] Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:18 (2010), 1675–1685.
174. [174] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Et al; NASH clinical research network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet 385:9972 (2015), 956–965.
175. [175] Giglio, R.V., Patti, A.M., Nikolic, D., Li Volti, G., Al-Rasadi, K., Katsiki, N., et al. The effect of bergamot on dyslipidemia. Phytomedicine, 2015 Dec 30 [Epub ahead of print].
176. [176] Patti, A.M., Al-Rasadi, K., Katsiki, N., Banerjee, Y., Nikolic, D., Vanella, L., et al. Effect of a natural supplement containing Curcuma longa, Guggul, and chlorogenic acid in patients with metabolic syndrome. Angiology 66:9 (2015), 856–861.
177. [177] Patti, A.M., Katsiki, N., Nikolic, D., Al-Rasadi, K., Rizzo, M., Nutraceuticals in lipid-lowering treatment: A narrative review on the role of chitosan. Angiology 66:5 (2015), 416–421.
178. [178] Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 45:4 (2015), 363–377.
179. [179] Parker, H.M., Johnson, N.A., Burdon, C.A., Cohn, J.S., O'Connor, H.T., George, J., Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 56:4 (2012), 944–951.
180. [180] Pacana, T., Sanyal, A.J., Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 15:6 (2012), 641–648.
181. [181] Musso, G., Cassader, M., Rosina, F., Gambino, R., Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomized trials. Diabetologia 55:4 (2012), 885–904.
182. [182] Suksomboon, N., Poolsup, N., Sinprasert, S., Effects of vitamin E supplementation on glycaemic control in type 2 diabetes: Systematic review of randomized controlled trials. J Clin Pharm Ther 36:1 (2011), 53–63.
183. [183] Katsiki, N., Manes, C., Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. Clin Nutr 28:1 (2009), 3–9.
184. [184] Popov, V.B., Lim, J.K., Treatment of nonalcoholic fatty liver disease: the role of medical, surgical, and endoscopic weight loss. J Clin Transl Hepatol 3:3 (2015), 230–238.
185. [185] Marchesini, G., Petta, S., Dalle, G.R., Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology, 11, 2015 Dec [Epub ahead of print].
186. [186] Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:2 (2015), 367–378.
187. [187] Aguilar-Olivos, N.E., Almeda-Valdes, P., CA, A.-S., Uribe, M., Méndez-Sánchez, N., The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism 65 (2015), 1196–1207 [Epub ahead of print].
188. [188] Mummadi, R.R., Kasturi, K.S., Chennareddygari, S., Sood, G.K., Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6:12 (2008), 1396–1402.
189. [189] Rouabhia, S., Milic, N., Abenavoli, L., Metformin in the treatment of non-alcoholic fatty liver disease: Safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol 8:4 (2014), 343–349.
190. [190] Doycheva, I., Loomba, R., Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): When to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther 31:1 (2014), 30–43.
191. [191] Ozturk, Z.A., Kadayifci, A., Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 6:4 (2014), 199–206.
192. [192] Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., Belfiore, A., Nonalcoholic fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 14:11 (2013), 22933–22966.
193. [193] Rakoski, M.O., Singal, A.G., Rogers, M.A., Conjeevaram, H., Meta-analysis: Insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 32:10 (2010), 1211–1221.
194. [194] Shah, P., Mudaliar, S., Pioglitazone: Side effect and safety profile. Expert Opin Drug Saf 9:2 (2010), 347–354.
195. [195] Ciudin, A., Hernandez, C., Simó, R., Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem 12:6 (2012), 585–604.
196. [196] http://www.fda.gov/Drugs/DrugSafety/ucm476466.htm [Assessed April 30, 2016].
197. [197] Monami, M., Vitale, V., Ambrosio, M.L., Bartoli, N., Toffanello, G., Ragghianti, B., et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Adv Ther 29:9 (2012), 736–746.
198. [198] Liu, J., Wang, G., Jia, Y., Xu, Y., GLP-1 receptor agonists: Effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev 31:4 (2015), 329–335.
199. [199] Lee, J., Hong, S.W., Rhee, E.J., Lee, W.Y., GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab J 36:4 (2012), 262–267.
200. [200] Gluud, L.L., Knop, F.K., Vilsbøll, T., Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open, 4(12), 2014, e005325.
201. [201] Taher, J., Baker, C.L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., et al. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Mol Metab 3:9 (2014), 823–833.
202. [202] Kim, S., Jung, J., Kim, H., Heo, R.W., Yi, C.O., Lee, J.E., et al. Exendin-4 improves nonalcoholic fatty liver disease by regulating glucose transporter 4 expression in ob/ob mice. Korean J Physiol Pharmacol 18:4 (2014), 333–339.
203. [203] Shao, N., Kuang, H.Y., Hao, M., Gao, X.Y., Lin, W.J., Zou, W., Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev 30:6 (2014), 521–529.
204. [204] Bi, Y., Zhang, B., Xu, W., Yang, H., Feng, W., Li, C., et al. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes. Acta Diabetol 51:5 (2014), 865–873.
205. [205] Vinodraj, K., Nagendra Nayak, I.M., Rao, J.V., Mathai, P., Chandralekha, N., Nitasha, B., et al. Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats. Indian J Pharmacol 47:2 (2015), 181–184.
206. [206] Ao, N., Yang, J., Wang, X., Du, J., Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol Res., 4, 2015 Jul [Epub ahead of print].
207. [207] Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, placebo-controlled phase 2 study. Lancet 387:10019 (2016), 679–690.
208. [208] Athyros, V.G., Katsiki, N., Mikhailidis, D.P., Resolution of Non-Alcoholic-Steatohepatitis. More than one drug needed?. Curr Vasc Pharmacol, 2016 in press.
209. [209] Gimeno-Orna, J.A., Verdes-Sanz, G., Borau-Maorad, L., Campos-Fernández, J., Lardiés-Sánchez, B., Monreal-Villanueva, M., En representación de la Sociedad Aragonesa de Endocrinología y Nutrición (SADEN). Baseline ALT levels as a marker of glycemic response to treatment with GLP-1 receptor agonists. Endocrinol Nutr, 2016 [Epub ahead of print].
210. [210] Blaslov, K., Bulum, T., Zibar, K., Duvnjak, L., Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 20:23 (2014), 7356–7365.
211. [211] Katsiki, N., Papanas, N., Mikhailidis, D.P., Dapagliflozin: More than just another oral glucose-lowering agent?. Expert Opin Investig Drugs 19:12 (2010), 1581–1589.
212. [212] Nakano, S., Katsuno, K., Isaji, M., Nagasawa, T., Buehrer, B., Walker, S., et al. Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice. J Clin Exp Hepatol 5:3 (2015), 190–198.
213. [213] Suzuki, M., Takeda, M., Kito, A., Fukazawa, M., Yata, T., Yamamoto, M., et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes, 4, 2014, e125.
214. [214] Singh, S., Khera, R., Allen, A.M., Murad, M.H., Loomba, R., Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 62:5 (2015), 1417–1432.
215. [215] Du, J., Ma, Y.Y., Yu, C.H., Li, Y.M., Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 20:2 (2014), 569–577.
216. [216] Zeng, T., Zhang, C.L., Zhao, X.L., Xie, K.Q., Pentoxifylline for the treatment of nonalcoholic fatty liver disease: A meta-analysis of randomized double-blind, placebo-controlled studies. Eur J Gastroenterol Hepatol 26:6 (2014), 646–653.
217. [217] Goh, G.B., Pagadala, M.R., Dasarathy, J., Unalp-Arida, A., Sargent, R., Hawkins, C., et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 35:3 (2015), 979–985.
218. [218] de Macêdo S, M., TA, G., JD, F., SH, S.S., The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 62 (2014), 189–196.
219. [219] Tziomalos, K., Athyros, V.G., Paschos, P., Karagiannis, A., Nonalcoholic fatty liver disease and statins. Metabolism 64:10 (2015), 1215–1223.
220. [220] Pastori, D., Polimeni, L., Baratta, F., Pani, A., Del Ben, M., Angelico, F., The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 47:1 (2015), 4–11.
221. [221] Eslami, L., Merat, S., Malekzadeh, R., Nasseri-Moghaddam, S., Aramin, H., Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev, 12, 2013, CD008623.
222. [222] Katsiki, N., Athyros, V.G., Karagiannis, A., Mikhailidis, D.P., The role of statins in the treatment of type 2 diabetes mellitus: An update. Curr Pharm Des 20:22 (2014), 3665–3674.
223. [223] Athyros, V.G., Tziomalos, K., Gossios, T.D., Griva, T., Anagnostis, P., Kargiotis, K., et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin And Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 376:9756 (2010), 1916–1922.
224. [224] Athyros, V.G., Giouleme, O., Ganotakis, E.S., Elisaf, M., Tziomalos, K., Vassiliadis, T., et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 7:5 (2011), 796–805.
225. [225] Tikkanen, M.J., Fayyad, R., Faergeman, O., Olsson, A.G., Wun, C.C., Laskey, R., et al., Investigators, I.D.E.A.L., Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 168 (2013), 3846–3852.
226. [226] Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R.M., Pipitone, R., Karja, V., et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 63:3 (2015), 705–712.
227. [227] Kargiotis, K., Athyros, V.G., Giouleme, O., Katsiki, N., Katsiki, E., Anagnostis, P., et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 21:25 (2015), 7860–7868.
228. [228] Kargiotis, K., Katsiki, N., Athyros, V.G., Giouleme, O., Patsiaoura, K., Katsiki, E., et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: A preliminary report. Curr Vasc Pharmacol 12:3 (2014), 505–511.
229. [229] Hyogo, H., Tazuma, S., Arihiro, K., Iwamoto, K., Nabeshima, Y., Inoue, M., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 57:12 (2008), 1711–1718.
230. [230] Hyogo, H., Ikegami, T., Tokushige, K., Hashimoto, E., Inui, K., Matsuzaki, Y., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 41:11 (2011), 1057–1065.
231. [231] Kimura, Y., Hyogo, H., Yamagishi, S., Takeuchi, M., Ishitobi, T., Nabeshima, Y., et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 45:7 (2010), 750–757.
232. [232] Nelson, A., Torres, D.M., Morgan, A.E., Fincke, C., Harrison, S.A., A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 43:10 (2009), 990–994.
233. [233] Nakahara, T., Hyogo, H., Kimura, Y., Ishitobi, T., Arihiro, K., Aikata, H., et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 42:11 (2012), 1065–1072.
234. [234] Han, K.H., Rha, S.W., Kang, H.J., Bae, J.W., Choi, B.J., Choi, S.Y., et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol 6:4 (2012), 340–351.
235. [235] Katsiki, N., Athyros, V.G., Karagiannis, A., Achieving lipid targets in primary care settings. Curr Med Res Opin 30:10 (2014), 1971–1974.
236. [236] Kolovou, G.D., Anagnostopoulou, K.K., Salpea, K.D., Daskalopoulou, S.S., Mikhailidis, D.P., The effect of statins on postprandial lipemia. Curr Drug Targets 8:4 (2007), 551–560.
237. [237] Papademetriou, V., Katsiki, N., Doumas, M., Faselis, C., Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des 20:40 (2014), 6339–6349.
238. [238] Athyros, V.G., Katsiki, N., Karagiannis, A., Mikhailidis, D.P., Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother 16:10 (2015), 1449–1461.
239. [239] Desai, C.S., Martin, S.S., Blumenthal, R.S., Non-cardiovascular effects associated with statins. BMJ, 349, 2014, g3743.
240. [240] Athyros, V.G., Kakafika, A.I., Tziomalos, K., Karagiannis, A., Mikhailidis, D.P., Pleiotropic effects of statins – clinical evidence. Curr Pharm Des 15:5 (2009), 479–489.
241. [241] Blais, P., Lin, M., Kramer, J.R., El-Serag, H.B., Kanwal, F., Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia. Dig Dis Sci, 2015 [Epub ahead of print].
242. [242] Athyros, V.G., Tziomalos, K., Daskalopoulos, G.N., Karagiannis, A., Mikhailidis, D.P., Statin-based treatment for cardiovascular risk and non -alcoholic fatty liver disease. Killing two birds with one stone?. Ann Med 43:3 (2011), 167–171.
243. [243] Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 8:3 Suppl. (2014), S47–S57.
244. [244] Lin, S.C., Ang, B., Hernandez, C., Bettencourt, R., Jain, R., Salotti, J., et al. Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: A secondary analysis of the MOZART trial. Therap Adv Gastroenterol 9:2 (2016), 152–161.
245. [245] Lioudaki, E., Ganotakis, E.S., Mikhailidis, D.P., Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 9:1 (2011), 62–86.
246. [246] Katsiki, N., Theocharidou, E., Karagiannis, A., Athyros, V.G., Mikhailidis, D.P., Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 19:17 (2013), 3107–3114.
247. [247] Oza, N., Takahashi, H., Eguchi, Y., Kitajima, Y., Kuwashiro, T., Ishibashi, E., et al. Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. Hepatol Res. 44:7 (2014), 812–817.
248. [248] Park, H., Shima, T., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 46:1 (2011), 101–107.
249. [249] Wierzbicki, A.S., Oben, J., Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 23:4 (2012), 345–352.
250. [250] Takeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K., et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial. Diabetologia 57:5 (2014), 878–890.
251. [251] Husain, N.E., Hassan, A.T., Elmadhoun, W.M., Ahmed, M.H., Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): What are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?. Expert Opin Drug Saf 14:9 (2015), 1445–1455.
252. [252] Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:25 (2015), 2387–2397.
253. [253] Murphy, S.A., Cannon, C.P., Blazing, M.A., Giugliano, R.P., White, J.A., Lokhnygina, Y., et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol 67:4 (2016), 353–361.
254. [254] Katsiki, N., Athyros, V.G., Mikhailidis, D.P., More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Hormones (Athens) 15:1 (2016), 5–7.
255. [255] Rizzo, M., Montalto, G., Al-Rasadi, K., Treatment options for managing atherogenic dyslipidemia and fatty liver disease. Expert Opin Pharmacother 15:8 (2014), 1065–1068.
256. [256] Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D.P., Rizzo, M., The role of fibrate treatment in dyslipidemia: An overview. Curr Pharm Des 19:17 (2013), 3124–3131.
257. [257] Gandhi, N., Lenton, R., Bhartia, M., Abbas, A., Raju, J., Ramachandran, S., Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus, 3, 2014, 14.
258. [258] Tziomalos, K., Lipid-lowering agents in the management of nonalcoholic fatty liver disease. World J Hepatol. 6:10 (2014), 738–744.
259. [259] Ganji, S.H., Kashyap, M.L., Kamanna, V.S., Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism 64:9 (2015), 982–990.
260. [260] Ganji, S.H., Kukes, G.D., Lambrecht, N., Kashyap, M.L., Kamanna, V.S., Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 306:4 (2014), G320–G327.
261. [261] Hu, M., Chu, W.C., Yamashita, S., Yeung, D.K., Shi, L., Wang, D., et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J Lipid Res 53:4 (2012), 802–809.
262. [262] Fabbrini, E., Mohammed, B.S., Korenblat, K.M., Magkos, F., McCrea, J., Patterson, B.W., et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95 (2010), 2727–2735.
263. [263] Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
264. [264] HPS2-THRIVE Collaborative Group, MJ, L., Haynes, R., JC, H., Parish, S., Aung, T., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371:3 (2014), 203–212.
265. [265] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Tredaptive,_ Pelzont_and_Trevaclyn/human_referral_prac_000014.jsp&mid=WC0b01ac05805c516f [Assessed April 30, 2016].
266. [266] Le, T.A., Chen, J., Changchien, C., Peterson, M.R., Kono, Y., Patton, H., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
267. [267] Merat, S., Aduli, M., Kazemi, R., Sotoudeh, M., Sedighi, N., Sohrabi, M., et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 53 (2008), 2246–2250.
268. [268] Ishitobi, T., Hyogo, H., Tokumo, H., Arihiro, K., Chayama, K., Efficacy of probucol for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label pilot study. Hepatol Res 44:4 (2014), 429–435.
269. [269] Athyros, V.G., Katsiki, N., Karagiannis, A., Is targeting microRNAs the philosopher's stone for vascular disease?. Curr Vasc Pharmacol 14:1 (2016), 88–97.
270. [270] Athyros, V.G., Katsiki, N., Karagiannis, A., Editorial: microRNAs: Potential targets for the treatment of cardiovascular disease. Curr Vasc Pharmacol 13:3 (2015), 366–367.
271. [271] Afonso, M.B., Rodrigues, P.M., Simão, A.L., Castro, R.E., Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med., 5(3), 2016.
272. [272] Szabo, G., Csak, T., Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci, 2016 Jan 14 [Epub ahead of print].
273. [273] Fuchs, C.D., Traussnigg, S.A., Trauner, M., Nuclear receptor modulation for the treatment of nonalcoholic fatty liver disease. Semin Liver Dis 36:1 (2016), 69–86.
274. [274] Petta, S., Valenti, L., Bugianesi, E., Targher, G., Bellentani, S., Bonino, F., Special interest group on personalised hepatology of the Italian Association for the Study of the Liver (AISF); special interest group on personalised hepatology of the Italian Association for the Study of the Liver AISF. A “systems medicine” approach to the study of non-alcoholic fatty liver disease. Dig Liver Dis 48:3 (2016), 333–342.
275. [275] Clarke, J.D., Cherrington, N.J., Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 151 (2015), 99–106.
276. [276] Gallego-Durán, R., Romero-Gómez, M., Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol 7:24 (2015), 2497–2502.
277. [277] Shaker, M., Tabbaa, A., Albeldawi, M., Alkhouri, N., Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. World J Gastroenterol 20:18 (2014), 5320–5330.
278. [278] Burra, P., Germani, G., Orthotopic liver transplantation in non-alcoholic fatty liver disease patients. Rev Recent Clin Trials 9:3 (2014), 210–216.
279. [279] Zezos, P., Renner, E.L., Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 20:42 (2014), 15532–15538.
280. [280] Go, G.W., Low-density lipoprotein receptor-related protein 6 (LRP6) is a novel nutritional therapeutic target for hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis. Nutrients 7:6 (2015), 4453–4464.
281. [281] Nikolic, D., Mikhailidis, D.P., Davidson, M.H., Rizzo, M., Banach, M., ETC-1002: A future option for lipid disorders?. Atherosclerosis 237:2 (2014), 705–710.
282. [282] Pinkosky, S.L., Filippov, S., Srivastava, R.A., Hanselman, J.C., Bradshaw, C.D., Hurley, T.R., et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 54:1 (2013), 134–151.
283. [283] Rodríguez, A.J., Neeman, T., Giles, A.G., Mastronardi, C.A., Paz, F.G., Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints. Arq Bras Endocrinol Metabol 58:8 (2014), 783–797.
284. [284] Takaki, A., Kawai, D., Yamamoto, K., Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 15:5 (2014), 7352–7379.
285. [285] Padmalayam, I., Suto, M., Role of adiponectin in the metabolic syndrome: Current perspectives on its modulation as a treatment strategy. Curr Pharm Des 19:32 (2013), 5755–5763.
286. [286] Polyzos, S.A., Kountouras, J., Anastasilakis, A.D., Geladari, E.V., Mantzoros, C.S., Irisin in patients with nonalcoholic fatty liver disease. Metabolism 63:2 (2014), 207–217.
287. [287] Arias-Loste, M.T., Ranchal, I., Romero-Gómez, M., Crespo, J., Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci 15:12 (2014), 23163–23178.
288. [288] Boström, P.A., Fernández-Real, J.M., Mantzoros, C., Irisin in humans: Recent advances and questions for future research. Metabolism 63:2 (2014), 178–180.
289. [289] Batirel, S., Bozaykut, P., Mutlu Altundag, E., Kartal Ozer, N., Mantzoros, C.S., The effect of irisin on antioxidant system in liver. Free Radic Biol Med, 75(Suppl. 1), 2014, S16.
290. [290] Minemura, M., Shimizu, Y., Gut microbiota and liver diseases. World J Gastroenterol 21:6 (2015), 1691–1702.
291. [291] Zhu, L., Baker, R.D., Baker, S.S., Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res 77:1–2 (2015), 245–251.
292. [292] Banach, M., Rizzo, M., Obradovic, M., Montalto, G., Rysz, J., Mikhailidis, D.P., et al. PCSK9 inhibition – a novel mechanism to treat lipid disorders?. Curr Pharm Des 19:21 (2013), 3869–3877.
293. [293] Mikhailidis, D.P., Athyros, V.G., Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 11:2 (2014), 72–74.
294. [294] Ajufo, E., DJ, R., Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol, 2016 Mar 21 [Epub ahead of print].
295. [295] http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/07/news_detail_002377.jsp&mid=WC0b01ac058004d5c1 [Assessed April 30, 2016].
296. [296] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003766/smops/Positive/human_smop_000828.jsp&mid=WC0b01ac058001d127 [Assessed April 30, 2016].
297. [297] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm [Assessed April 30, 2016].
298. [298] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm [Assessed April 30, 2016].
299. [299] Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:16 (2015), 1489–1499.
300. [300] Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:16 (2015), 1500–1509.
301. [301] Demers, A., Samami, S., Lauzier, B., Des Rosiers, C., Sock, E.T., Ong, H., et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol 35:12 (2015), 2517–2525.